London, United Kingdom
Pulmocide, a biopharmaceutical company founded in 2013 and based in the United Kingdom, is pioneering the development of inhaled medicines for the targeted treatment of life-threatening respiratory diseases. Their core focus is on serious respiratory fungal infections, particularly pulmonary aspergillosis, which pose significant threats to patients' quality of life.
The company's approach centers around Opelconazole, an inhaled therapy designed to deliver high drug concentrations directly to the lung infection site while minimizing systemic exposure. This innovative delivery method holds potential for improved patient outcomes by minimizing systemic side effects and drug interactions.
Pulmocide's expertise in inhaled therapies positions them as a leader in the respiratory disease space. With a recent $52.00M Series C funding round helmed by prominent investors like F-Prime Capital and Johnson & Johnson Innovation – JJDC, Pulmocide is well-poised to bring crucial solutions to underserved areas of respiratory healthcare.
F2G